Excipients play a key role in helping pharmaceutical manufacturers serve patients better through improved compliance and efficacy of treatment. They also help reduce developmental costs and provide opportunities to differentiate products through new modes of drug delivery.
This review discusses challenges to stability, analytics and manufacturing of protein coformulations. Furthermore, general considerations to be taken into account for the pharmaceutical development of coformulated protein drug products are highlighted.